Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?

Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod

(2016) Amy K. Forrestel et al.   JAMA Neurology

Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod

(2015) DeRen Huang   NEUROLOGY

Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod

(2015) T. Tully et al.   NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient

(2014) AK Artemiadis et al.   Multiple Sclerosis Journal

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

(2011) M. C. Kowarik et al.   NEUROLOGY

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY